This stock is not going to linger here much longer. Bad news on any of the drugs and we know it will tank. I would like to highlight the following:
1) The December hiring of Josh Disbrow as COO in December
2) No inside selling and director Richard Giles exercised 50,417 shares at a price of $2.20 - $2.76; that event along indicated nothing would happen before February 17.
3) The February 11 Luoxis Diagnostics announcement included the statement "securing commercialization partners world-wide for the Zertane sexual dysfunciton drug portfolio." Again execution is the question but this is not a quick process and is why Josh Disbrow was hired.
In conclusion be smart about your position size but I see no reason to either panic or celebrate at this time.